Mikronährstoffe in der Onkologie

Übersicht
MMP
Mikronährstoffe in der Onkologie
Aktuelles zu Vitamin D, Selen, L-Carnitin und Vitamin C
Uwe Gröber, Essen, Ralph Mücke, Lemgo/Herne, Peter Holzhauer, Oberaudorf/Essen, und
Klaus Kisters, Herne/Essen
Literatur
1.Abbas S, Linseisen J, Slanger T, Kropp S, et al. Serum 25-hydroxy­
vitamin D and risk of post-menopausal breast cancer – results of a large
case-control study. Carcinogenesis 2008;29:93–9.
2.Andrieu-Abadie N, Jaffrezou JP, Hatem S, et al. L-carnitine prevents
doxorubicin-induced apoptosis of cardiac myocytes: role of inhibition of
ceramide generation. FASEB J 1999;13:1501–10.
3.Arends J, Bodoky G, Bozzetti F, Fearon K, et al.; DGEM (German
­Society for Nutritional Medicine); ESPEN (European Society for Par­
enteral and Enteral Nutrition). ESPEN Guidelines on Enteral Nutrition:
Non-surgical oncology. Clin Nutr, 2006;25:245–59.
4.Asfour IA, El-Tehewi MM, Ahmed MH, et al. High-dose sodium selenite can induce apoptosis of lymphoma cells in adult patients with nonHodgkin’s lymphoma. Biol Trace Elem Res 2009;127:200–10.
5.Asfour IA, Fayek MH, Raouf S, et al. The impact of high-dose sodium
selenite therapy on Bcl-2 expression in adult non-Hodgkin’s lymphoma
patients: correlation with response and survival. Biol Trace Elem Res
2007;120:1–10.
6.Asfour IA, Shazly SE, Fayek MH, et al. Effect of high-dose sodium
selenite therapy on polymorphonuclear leukocyte apoptosis in nonHodgkin’s lymphoma patients. Biol Trace Elem Res 2006;110:19–32.
7.Bianchi G, Vitali G, Caraceni A, Ravaglia S, et al. Symptomatic and
neuro­physiological responses of paclitaxel- or cisplatin-induced neuro­
pathy to oral acetyl-L-carnitine. Eur J Cancer 2005;41:1746–50.
8.Bleys J, Navas-Acien A, Guallar E. Serum selenium levels and all cause,
cancer, and cardiovascular mortality among US adults. Arch Intern Med
2008;168:404–10.
9.Block K, Koch A, Mead M, Newman RA, et al. Should supplemental
anti­oxidant administration be avoided during chemotherapy and radia­
tion therapy? J Natl Cancer Inst 2009;101:124–5.
10.Block KI, Koch AC, Mend MN, Tothy PK, et al. Impact of antioxidant
supplementation on chemotherapeutic efficacy: a systematic review
of the evidence from randomized controlled trials. Cancer Treat Rev
2007;33:407–18.
11. Block KI, Koch AC, Mend MN, Tothy PK, et al. Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer
2008;123:1227–39.
12.Block KI. Antioxidants and cancer therapy: furthering the debate. Integr
Cancer Ther 2004;3:342–8.
13.Bozzetti F, SCRINIO Working Group. Screening the nutritional status
in oncology: a preliminary report on 1,000 outpatients. Support Care
­Cancer 2009;17:279–84.
14.Brown JK, Byers T, Doyle C, et al., American Cancer Society. Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J Clin
2003;53:268–91.
15.Büntzel J, Bruns F, Glatzel M, Garayev A, et al. Zinc concentrations
in serum during head and neck cancer progression. Anticancer Res
2007;27:1941–3.
16.Büntzel J, Riesenbeck D, Glatzel M, et al. Limited effects of selenium
substitution in the prevention of radiation-associated toxicities. Results
of a randomized study in head neck cancer patients. Anticancer Res
2010;30:1829–32.
17.Carmel AS, Shieh A, Bang H, Bockman RS. The 25(OH)D level needed
to maintain a favourable bisphosphonate response is ≥ 33 ng/ml. Osteoporos Int 2012;23:2479–87.
18.Chang D, Wang F, Zhao YS, Pan HZ. Evaluation of oxidative stress in
colorectal cancer patients. Biomed Environ Sci 2008;21:286–9.
19.Chao HH, Liu JC, Hong HJ, et al. L-carnitine reduces doxorubicin-­
induced apoptosis through a prostacyclin-mediated pathway in neonatal
rat cardiomyocytes. Int J Cardiol 2011;146:145–52.
20.Chen MF, Yang CM, Su CM, Liao JW, et al. Inhibitory effect of vitamin C in combination with vitamin K3 on tumor growth and metastasis
of Lewis lung carcinoma xenografted in C57BVL/6 mice. Nutr Cancer
2011;63:1036–43.
21.Chen Q, Espey MG, Sun AY, et al. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in
extracellular fluid in vivo. Proc Natl Acad Sci U S A 2007;104:8749–54.
22.Chen Q, Espey MG, Sun AY, Pooput C, et al. Pharmacologic doses of
ascorbate act as prooxidant and decrease growth of aggressive tumor xenografts in mice. PNAS 2008;105:11037–8.
23.Churilla TM, Brereton HD, Klem M, Peters CA. Vitamin D deficiency
is widespread in cancer patients and correlates with advanced stage dis­
ease: A community oncology experience. Nutr Cancer 2012;64:521–5.
Uwe Gröber, Akademie für Mikronährstoffmedizin, Zweigertstraße 55,
45130 Essen, E‑Mail: [email protected]
Dr. med. Ralph Mücke, Klinik für Strahlentherapie, Klinikum Lippe GmbH,
Rintelner Straße 85, 32657 Lemgo und Klinik für Strahlentherapie und RadioOnkologie, Ruhr Universität Bochum, Hölkeskampring 40, 44625 Herne
Dr. Peter Holzhauer, Klinik Bad Trissl GmbH, Innere Medizin II – Onkologie und
Komplementärmedizin, Bad-Trissl-Straße 73, 83080 Oberaudorf und Akademie
für Mikronährstoffmedizin, Zweigertstraße 55, 45130 Essen
Prof. Dr. med. Klaus Kisters, St. Anna Hospital, Medizinische Klinik I,
Hospitalstraße 19, 44649 Herne und Akademie für Mikronährstoffmedizin,
Zweigertstraße 55, 45130 Essen
MMP 36. Jahrgang 4/2013
1
MMP
Übersicht Mikronährstoffe in der Onkologie
24.Clark LC, Combs GF, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. J Am Med Assoc 1996;276:1957–63.
25.Clemens MR, Ladner C, Ehninger G, Einsele H, et al. Plasma vitamin E
and beta-carotene concentrations during radiochemotherapy preceding
bone marrow transplantation. Am J Clin Nutr 1990;51:216–9.
26.Clemens MR, Müller-Ladner CI, Gey KF. Vitamins during high dose
chemo- and radiotherapy. Z Ernährungswiss 1992;31:110–20.
27.Crew KD, Shane E, Cremers S, McMahon DJ, et al. High prevalence of
vitamin D deficiency despite supplementation in premenopausal women
with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol
2009;27:2151–6.
28.Cruciani RA, Dvorkin E, Homel P, Culliney B, et al. L-carnitine supple­
mentation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: a preliminary analysis. Ann N Y Acad Sci
2004;1033:168–76.
29.Cruciani RA, Dvorkin E, Homel P, et al. Safety, tolerability and symptom
outcomes associated with L-carnitine supplementation in patients with
cancer, fatigue, and carnitine deficiency: a phase I/II study. J Pain Sym­
ptom Manage 2006;32:551–9.
30.D’Andrea G. Use of antioxidants during chemotherapy and radiotherapy
should be avoided. CA Cancer J Clin 2005;55:319–21.
31.Dabak DO, Kuloglu T, Ozercan MR. Effects of vitamin D3 (cholecalciferol) on adriamycin-induced nephrotoxicity. Ren Fail 2009;31:400–5.
32.De Grandis D. Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: a short review. CNS Drugs
2007;21(Suppl 1):39–43.
33.Delaney CE, Hopkins SP, Addison CL. Supplementation with L-carnitine does not reduce the efficacy of epirubicin treatment in breast cancer
cells. Cancer Lett 2007;252:195–207.
34.Dennert G, Zwahlen M, Brinkman M, et al. Selenium for preventing cancer (Review). Cochrane Database Syst Rev 2011;11(5):CD005195.
35.DeWys WD, Begg C, Lavin PT, Band PR, et al. Prognostic effect of
weight loss prior to chemotherapy in cancer patients. Eastern ­Cooperative
Oncology Group. Am J Med 1980;69:491–7.
36.Dormand EL, Banwell PE, Goodacre TE. Radiotherapy and wound
healing. Int Wound J 2005;2:112–27.
37.Drake MT, Maurer MJ, Link BK, Habermann TM, et al. Vitamin D insufficiency and prognosis in non-Hodgkin’s lymphoma. J Clin Oncol
2010;28:4191–8.
38.Drisko JA, Chapman J, Hunter VJ. the use of antioxidants with firstline chemotherapy in two cases of ovarian cancer. J Am Coll Nutr
2003;22:118–23.
39.Duffield-Lillico AJ, Dalkin BL, Reid ME, et al. Nutritional prevention of
cancer study group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete
treatment period of the Nutritional Prevention of Cancer Trial. BJU Int
2003;91:608–12.
40.Fakih MG, Trump DL, Johnson CS, Tian L, et al. Chemotherapy is linked
to severe vitamin D deficiency in patients with colorectal cancer. Int J
Colorectal Dis 2009;24:219–24.
41.Fearon KC, Voss AC, Hustend DS. Definition of cancer cachexia: effect
of weight loss, reduced food intake and systemic inflammation on functional status and prognosis. Am J Clin Nutr 2006;83:1345–50.
42.Fink M. Vitamin D deficiency is a cofactor of chemotherapy-induced
mucocutaneous toxicity and dysgeusia. J Clin Oncol 2011;29:e81–8.
43.Garland CF, Gorham ED, Mohr SB, Garland FC. Vitamin D for cancer
prevention: global perspective. Ann Epidemiol 2009;19:468–83.
44.Goodwin PJ, Ennis M, Pritchard KI, Koo J, et al. Prognostic effects
of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol
2009;27:3757–63.
45.Gorham ED, Garland CF, Garland FC, Grant WB, et al. Optimal vitamin D status for colorectal cancer prevention: a quantitative meta-ana­
lysis. Am J Prev Med 2007;32:210–6.
46.Grant M, Kravits K. Symptoms and their impact on nutrition. Semin
Oncol Nurs 2000;16:113–21.
47.Gröber U, Holick MF, Kisters K. Vitamin D3 und Arzneimittel. Med
Monats­schr Pharm 2011;34:377–87.
48.Gröber U, Hübner J, Holzhauer P, Kleeberg UR. Antioxidanzien und
andere Mikronährstoffe in der komplementären Onkologie. Onkologe
2010;16:73–9.
2
MMP 36. Jahrgang 4/2013
49.Gröber U, Hübner J, Holzhauer P. Vitamin C in der komplementären Onkologie. Der Onkologe 2010;16:303–13.
50.Gröber U, Kisters K. Influence of drugs on vitamin D and calcium metabolism. Dermatoendocrinol 2012;4:158–66.
51.Gröber U. Antioxidants and other micronutrients in complementary
­oncology. Breast Care 2009;4:13–20.
52.Gröber U. Arzneimittel und Mikronährstoffe. 2. Auflage. Stuttgart:
Wissen­schaftliche Verlagsgesellschaft Stuttgart, 2012.
53.Gröber U. Mikronährstoffe. Metabolic Tuning – Prävention – Therapie.
Wissenschaftliche Verlagsgesellschaft Stuttgart, 2011.
54.Gröber U. Selen in der komplementären Onkologie. Med Monatsschr
Pharm 2010;33:140–2.
55.Gröber U. Vitamin C in der komlementären Onkologie. Update 2009.
Med Monatsschr Pharm 2009;32:263–7.
56.Gröber U. Vitamin D3, ein altes Vitamin im neuen Licht. Med Monatsschr Pharm 2010;33:376–83.
57.Haschke M, Vitins T, Lüde S, et al. Urinary excretion of carnitine as a
marker of proximal tubular damage associated with platin-based antineoplastic drugs. Nephrol Dial Transplant 2010;25:426–33.
58.Herst PM, Broadley KW, Harper JL, McConnell MJ. Pharmacological
concentrations of ascorbate radiosensitize glioblastoma multiforme primary cells by increasing oxidative DNA damage and inhibiting G2/M
arrest. Free Radic Biol Med 2012;52:1486–93.
59.Heuberger W, Berardi S, Jacky E, Pey P, et al. Increased urinary excretion of carnitine in patients treated with cisplatin. Eur J Clin Pharmacol
1998;54:503–8.
60.Hockenberry MJ, Hooke MC, Gregurich M, McCarthy K. Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin. J Pediatr Hematol Oncol 2009;31:664–9.
61.Holick MF. Stay tuned to PXR: an orphan actor that may not be D-structive only to bone. J Clin Invest 2005;115:32–4.
62.Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266–81.
63.Holick MF. Vitamin D: Physiology, molecular biology, and clinical applications. Second Edition. New York: Humana Press/Springer Science,
2010.
64.Holzhauer P, Gröber U. Checkliste: Komplementäre Onkologie. Stuttgart: Hippokrates Verlag, 2010.
65.Hu YJ, Chen Y, Zhang YQ, et al. The protective role of selenium on the
toxicity of cisplatinum-contained chemotherapy regimen in cancer patients. Biol Trace Elem Res 1997;56:331–41.
66.Jaakkola K, Lähteenmäki P, Laakso J, Harju E, et al. Treatment with
antioxidant and other nutrients in combination with chemotherapy
and irradiation in patients with small-cell lung cancer. Anticancer Res
1992;12:599–606.
67.Jatoi A, Williams B, Nichols F, et al. Is voluntary vitamin and mineral
supplementation associated with better outcome in non-small cell lung
cancer patients? Results from the Mayo Clinic lung cancer cohort. Lung
Cancer 2005;49:77–84.
68.Jatoi A, Williams BA, Marks R, et al. Exploring vitamin and mineral
supplementation and purported clinical effects in patients with small cell
lung cancer: results from the Mayo Clinic lung cancer cohort. Nutr Cancer 2005;51:7–12.
69.Jin HW, Flatters SJ, Xiao WH, Mulhern HL, et al. Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects
on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. Exp Neurol 2008;210:229–37.
70.Kamphuis MH, Geerlings MI, Grobbee DE, et al. Dietary intake of
B(6–9-12) vitamins, serum homocysteine levels and their association
with depressive symptoms: the Zutphen Elderly Study. Eur J Clin Nutr
2008;62:939–45.
71.Khan QJ, et al. Randomized trail of vitamin D3 to prevent worsening of musculoskeletal symptoms and fatigue in women with breast
cancer starting adjuvant letrozole: The VITAL trial. J Clin Oncol
2012;30(Suppl):abstr. 9000, ASCO-Kongress 2012.
72.Khan QJ, Reddy PS, Kimler BF, Sharma P, et al. Effect of vitamin D
supplementation on serum 25-hydroxy vitamin D levels, joint pain, and
fatigue in women starting adjuvant letrozole treatment for breast cancer.
Breast Cancer Res Treat 2010;119:111–8.
73.Kondo K, Fujiwara M, Murase M, Kodera Y, et al. Severe acute metabolic acidosis and Wernicke’s encephalopathy following chemotherapy
with 5-fluorouracil and cisplatin: case report and review of the literature.
Jpn J Clin Oncol 1996;26:234–6.
Mikronährstoffe in der Onkologie Übersicht
74.Kraft K. L-Carnitin Supplementierung in der Behandlung des fortgeschrittenen Pankreaskarzinoms (CARPAN-Studie). Inaugural-Dissertation, Ernst-Moritz-Universität, Greifswald, September 2011.
75.Kraft M, Kraft K, Gärtner S, Mayerle J, et al. L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN) – a randomized multicentre
trial. Nutr J 2012;11:52 (doi: 10.1186/1475-2891-11-52).
76.Kurbacher CM, Wagner U, Kolster B, Andreotti PE, et al. Ascorbic acid
(vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett
1996;103:183–9.
77.Lajer H, Kristensen M, Hansen HH, Christensen S, et al. Magnesium and
potassium homeostasis during cisplatin treatment. Cancer Chemother
Pharmacol 2005;55:231–6.
78.Lajer H, Kristensen M, Hansen HH, Nielsen S, et al. Magnesium depletion enhances cisplatin-induced nephrotoxicity. Cancer Chemother
Pharmacol 2005;56:535–42.
79.Laviano A, Meguid MM. Nutritional issues in cancer management. Nutrition 1996;12:358–71.
80.Lawenda BD, Kelly KM, Ladas EJ, et al. Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J Natl Cancer Inst 2008;100:773–83.
81.Leung EY, Crozier JE, Talwar D, O’Reilly DS, et al. Vitamin antioxidants, lipid peroxidation, tumour stage, the systemic inflammatory
response and survival in patients with colorectal cancer. Int J Cancer
2008;123:2460–8.
82.Lin CC, Yin MC. B vitamins deficiency and decreased anti-oxidative
state in patients with liver cancer. Eur J Nutr 2007;46:293–9.
83.Lin LC, Que J, Lin KL, et al. Effects of zinc supplementation on clinical outcomes in patients receiving radiotherapy for head and neck cancers: a double-blinded randomized study. Int J Radiat Oncol Biol Phys
2008;70:368–73.
84.Lin YS, Lin LC, Lin SW. Effects of zinc supplementation on the survival
of patients who received concomitant chemotherapy and radiotherapy for
advanced nasopharyngeal carcinoma: follow-up of a double-blind randomized study with subgroup analysis. Laryngoscope 2009;119:1348–52.
85.Lippmann SM, Klein EA, Goodman PJ, et al. Effect of selenium and
vitamin E on risk of prostate cancer and other cancers: The selenium and
vitamin E cancer prevention trial (SELECT). JAMA 2009;301:39–51.
86.Look MP, Musch E. Lipid peroxides in the polychemotherapy of cancer
patients. Chemotherapy 1994;40:8–15.
87.Lotti T, Rodofili C, Benci M, et al. Wound-healing problems associated
with cancers. J Wound Care 1998;7:81–4.
88.Ma Y, Trump DL, Johnson CS. Vitamin D in combination cancer treatment. J Cancer 2010;1:101–7.
89.Mackay J, Jemal A, Lee N, Parkin DM. The Cancer Atlas. American
­Cancer Society, 2006.
90.Madeddu C, Dessì M, Panzone F, Serpe R, et al. Randomized phase III
clinical trial of a combined treatment with carnitine + celecoxib ±
megest­rol acetate for patients with cancre-related anorexia/cachexia syndrome. Clin Nutr 2012;31:176–82.
91.Mantovani G, Macciò A, Madeddu C, Mura L, et al. Reactive oxygen
species, antioxidant mechanisms, and serum cytokine levels in cancer
patients: impact of an antioxidant treatment. J Environ Pathol Toxicol
Oncol 2003;22:17–28.
92.Mantovani G, Macciò A, Madeddu C, Mura L, et al. Reactive oxygen
species, antioxidant mechanisms and serum cytokine levels in cancer patients: impact of an antioxidant treatment. J Cell Mol Med 2002;6:570–
82.
93.Mantovani G, Macciò A, Madeddu C, Serpe R, et al. Randomized
phase III clinical trial of five different arms of treatment in 332 patients
with cancer cachexia. Oncologist 2010;15:200–11.
94.Marín Caro MM, Laviano A, Pichard C. Impact of nutrition on quality of
life during cancer. Curr Opin Clin Nutr Metab Care 2007;10:480–7.
95.Marthaler NP, Visarius T, Küpfer A, Lauterburg BH. Increased urinary
losses of carnitine during ifosfamide chemotherapy. Cancer Chemother
Pharmacol 1999;44:170–2.
96.Mayland C, Allen KR, Degg TJ, Bennet M. Micronutrient concentrations
in patients with malignant disease: effect of the inflammatory response.
Ann Clin Biochem 2004;41:138–41.
97.Mayland CR, Bennett MI, Allan K. Vitamin C deficiency in cancer patients. Palliat Med 2005;19:17–20.
MMP
98. Micke O, Bruns F, Glatzel M, et al. Predictive factors for the use of
complementary and alternative medicine (CAM) in radiation oncology.
Eur J Integrat Med 2009;1:22–30.
99. Moss RW. Should patients undergoing chemotherapy and radiotherapy
be prescribed antioxidants? Integr Cancer Ther 2006;5:63–82.
100. Mücke R, Schomburg L, Büntzel J, Gröber U, et al. Komplementärer
Seleneinsatz in der Onkologie. Onkologie 2010;16:181–6.
101. Mücke R, Schomburg L, Glatzel M. Multicenter, phase III trial comparing selenium supplementation with observation in gynecologic
­radiation oncology. Int J Radiation Oncology Biol Phys 2010;70:825–
35.
102. Mutschler E, Geisslinger G, Kroemer HK, et al. Mutschler Arzneimittel­
wirkungen: Pharmakologie – Klinische Pharmakologie – Toxikologie.
10. Auflage. Stuttgart: Wissenschaftliche Verlagsgesellschaft Stuttgart,
2013.
103. Nechuta S, Lu W, Chen Z, Zheng Y, et al. Vitamin supplement use during breast cancer treatment and survival: a prospective cohort study.
Cancer Epidemiol Biomarkers Prev 2011;20:262–71.
104. Niyikiza C, Baker SD, Seitz DE, Walling JM, et al. Homocysteine and
methylmalonic acid: markers to predict and avoid toxicity from peme­
trexed therapy. Mol Cancer Ther 2002;1:545–52.
105. Norman HA, Butrum RR, Feldman E, et al., The role of dietary supplements during cancer therapy. J Nutr 2003;133(Suppl 1):3794S–9S.
106. Ohe Y, Ichinose Y, Nakagawa K, Tamura T, et al. Efficacy and safety of
two doses of pemetrexed supplemented with folic acid and vitamin B12
in previously treated patients with non-small cell lung cancer. Clin Cancer Res 2008;14:4206–12.
107. Palan PR, Woodall AL, Anderson PS, Mikhail MS. Alpha-tocopherol
and alpha-tocopheryl quinone levels in cervical intraepithelial neoplasia and cervical cancer. Am J Obstet Gynecol 2004;190:1407–10.
108. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002.
CA Cancer J Clin 2005;55:74–108.
109. Prasad KN, et al. High doses of multiple antioxidant vitamins: essential
ingredients in improving the efficacy of standard therapy. J Am Coll
Nutr 1999;18:13–25.
110. Prasad KN. Multiple dietary antioxidants enhance the efficacy of standard and experimental cancer therapies and decrease their toxicity. Integr Cancer Ther 2004;3:310–22.
111. Prieto-Alhambra D, Javaid MK, Servitja S, Arden NK, et al. Vitamin D
threshold to prevent aromatase inhibitor-induced arthralgia: a prospec­
tive cohort study. Breast Cancer Res Treat 2011;125:869–78.
112. Ravasco P, Monteiro-Grillo I, Vidal PM, Camilo ME. Dietary counseling improves patient outcomes: a prospective, randomized, controlled
trial in colorectal cancer patients undergoing radiotherapy. J Clin Oncol
2005;23:1431–8.
113. Ringe JD, Kipshoven C. Vitamin D-insufficiency: An estimate of the
situation in Germany. Dermatoendocrinol 2012;4:72–80.
114. Russell ST, Tisdale MJ. The role of glucocorticoids in the induction of
zinc-alpha2-glycoprotein expression in adipose tissue in cancer cachexia. Br J Cancer 2005;92:876–81.
115. Santini D, Galluzzo S, Vincenzi B, Zoccoli A, et al. Longitudinal evaluation of vitamin D plasma levels during anthracycline- and docetaxelbased adjuvant chemotherapy in early-stage breast cancer patients. Ann
Oncol 2010;21:185–6.
116. Sayed-Ahmed MM, Salman TM, Gaballah HE, Abou El-Naga SA,
et al. Propionyl-L-carnitine as protector against adriamycin-induced
cardiomyopathy. Pharmacol Res 2001;43:513–20.
117. Schmoll HJ, Höffken K, Possinger K. Kompendium Internistische Onkologie Standards in Therapie und Diagnostik, Teil I–III. Heidelberg:
Springer, 2005.
118. Shimpo K, Nagatsu T, Yamada K, Sato T, et al. Ascorbic acid and adriamycin toxicity. Am J Clin Nutr 1991;54(Suppl 6):1298S–301S.
119. Shinozaki K, Hosokawa Y, Hazawa M, Kashiwakura I, et al. Ascorbic
acid enhances radiation-induced apoptosis in an HL60 human ­leukemia
cell line. J Radiat Res 2011;52:229–37.
120. Sieja K, Talerczyk M. Selenium as an element in the treatment of
ovarian cancer in women receiving chemotherapy. Gynecol Oncol
2004;93:320–7.
121. Skrzydlewska E, Sulkowski S, Koda M, Zalewski B, et al. Lipid peroxidation and antioxidant status in colorectal cancer. World J Gastroenterol
2005;11:403–6.
MMP 36. Jahrgang 4/2013
3
MMP
Übersicht Mikronährstoffe in der Onkologie
122. Stefanini M. Cutaneous bleeding related to zinc deficiency in two cases
of advanced cancer. Cancer 1999;86:866–70.
123. Ströhle A, Hahn A. Bedeutung von Mikronährstoffen für die Immunkompetenz. MMW Fortschr der Medizin 2009;3:133–41.
124. Ströhle A, Hahn A. Vitamin C and immune function. Med Monatsschr
Pharm 2009;32:49–54.
125. Ströhle A, Zänker K, Hahn A. Nutrition in oncology: the case of micronutrients. Oncol Rep 2010;24:815–28.
126. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev 2009;89:381–
410.
127. Tong H, Isenring E, Yates P. The prevalence of nutrition impact symptoms and their relationship to quality of life and clinical outcomes in
medical oncology patients. Support Care Cancer 2009;17:83–90.
128. Trump DL, Chadha MK, Sunga AY, Fakih MG, et al. Vitamin D deficiency and insufficiency among patients with prostate cancer. BJU Int
2009;104:909–14.
129. Tsao SM, Yin MC, Liu WH. Oxidant stress and B vitamins status in
patients with non-small cell lung cancer. Nutr Cancer 2007;59:8–13.
130. Vollbracht C, Schneider B, Leendert V, Weiss G, et al. Intravenous
vitamin C administration improves quality of life in breast cancer
patients during chemo-/radiotherapy and aftercare: results of a retro­
spective, multicentre, epidemiological cohort study in Germany. In
Vivo 2011;25:983–90.
4
MMP 36. Jahrgang 4/2013
131. Welsh JL, Wagner BA, Van‘t Erve TJ, et al. Pharmacological ascorbate
with gemcitabine for the control of metastastic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer
Chemother Pharmacol 2013 Feb 5. [Epub ahead of print].
132. Wenzel U, Nickel A, Daniel H. Increased carnitine-dependent fatty acid
uptake into mitochondria of human colon cancer cells induces apoptosis. J Nutr 2005;135:1510–4.
133. Yoon HR, Hong YM, Boriack RL, Bennett MJ. Effect of L-carnitine
supplementation on cardiac carnitine palmitoyltransferase activities
and plasma carnitine concentrations in adriamycin-treated rats. Pediatr
Res 2003;53:788–92.
134. Zittermann A, von Helden R, Grant WB, Kipshoven C, et al. An estimate of the survival benefit of improving vitamin D status in the adult
German population. Dermato-Endocrinology 2009;1:300–6.
135. Zittermann A. The estimated benefits of vitamin D for Germany. Mol
Nutr Food Res 2010;54:1164–71.
136. Zürcher G. Mangelernährung bei onkologischen Patienten. In:
Biesalski­, Köhrle, Schümann (Hrsg.). Vitamine, Spurenelemente und
Mineral­stoffe. Stuttgart: Thieme, 2002.
137. Zürcher G. Medikamentöse Strategien zur Gewichtszunahme bei
kachek­tischen Patienten. Akt Ernährungmed 2002;27:398–407.